Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal

Lentiviruses, such as human immunodeficiency virus type 1 (HIV-1), assemble at and bud through the cytoplasmic membrane. Both the matrix (MA) domain of Gag and its amino-terminal myristylation have been implicated in these processes. We have created HIV-1 proviruses lacking the entire matrix domain of gag which either lack or contain an amino-terminal myristate addition sequence at the beginning of the capsid domain. Myristate- and matrix-deficient [myr(-)MA(-)] viruses produced after transient transfection are still able to assemble into particles, although the majority do not form at the plasma membrane or bud efficiently. Myristylation of the amino terminus of the truncated Gag precursor permits a much more efficient release of the mutant virions. While myr(-)MA(-) particles were inefficient in proteolytic processing of the Gag precursor, myristylation enabled efficient proteolysis of the mutant Gag. All matrix-deficient viruses are noninfectious. Particles produced by matrix-deficient mutants contain low levels of glycoproteins, indicating the importance of matrix in either incorporation or stable retention of Env. Since matrix-deficient viruses contain a normal complement of viral genomic RNA, a role for MA in genomic incorporation can be excluded. Contrary to previous reports, the HIV-1 genome does not require sequences between the 5' splice donor site and the gag start codon for efficient packaging.

Medienart:

Artikel

Erscheinungsjahr:

1994

Erschienen:

1994

Enthalten in:

Zur Gesamtaufnahme - volume:68

Enthalten in:

Journal of virology - 68(1994), 10 vom: 15. Okt., Seite 6644-54

Sprache:

Englisch

Beteiligte Personen:

Lee, P P [VerfasserIn]
Linial, M L [VerfasserIn]

Themen:

0I3V7S25AW
Codon
Comparative Study
EC 2.7.7.49
Gene Products, gag
HIV Core Protein p24
HIV Reverse Transcriptase
Journal Article
Myristic Acid
Myristic Acids
Oligodeoxyribonucleotides
RNA, Neoplasm
RNA, Viral
RNA-Directed DNA Polymerase
Research Support, U.S. Gov't, P.H.S.
Viral Matrix Proteins

Anmerkungen:

Date Completed 13.10.1994

Date Revised 24.07.2020

published: Print

Citation Status MEDLINE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM074980327